High-end Cellomics Market Outlook (2023 to 2033)

The high-end cellomics market revenue totaled US$ 325.1 million in 2023, according to Future Market Insights (FMI) study. The overall sales of high-end cellomics are expected to reach US$ 639.2 million by 2033, capturing a CAGR of 7% from 2023 to 2033.

Recent developments in drug discovery and high-end cellomics have augmented pressure at the strategic points along the drug discovery pipeline, auguring well for the market’s future trends. The rising need to determine and study toxicity levels in the initial phase of drug discovery is driving market growth.

How does the Development of Advanced Imaging Systems Augment High-end Cellomics Market Growth?

  • High-end cellomics has gained significant traction for its ability to investigate various aspects of cell biology and the drug discovery and development process.
  • Technological breakthroughs have been observed in automated microscope hardware, sCMOS cameras, confocal optics, oil immersion objective lenses, and throughput capabilities of these systems.
  • Advanced imaging systems have also improved software data analysis and data management capabilities.
  • Industry players are focusing on introducing new products with advanced features.
  • Molecular Devices LLC introduced the ImageXpress Confocal HT.ai High Content HT.ai high content screening system in January 2021. It enables researchers to accelerate their study on phenotypic screening of organoid models, offering benefits such as quick image acquisition and multiplexing flexibility.
  • In December 2020, Molecular Devices LLC introduced water imaging technology for the ImageXpress Micro Confocal High-Content Imaging System. This technology allows the acquisition and analysis of 3D cell model assays, including spheroids, organoids, and organ-on-chip biology.
  • The availability of innovative products with associated benefits is expected to drive the adoption and growth of the global high-end cellomics industry.
Attributes Details
High-end Cellomics Market Value 2023 US$ 325.1 million
Estimated High-end Cellomics Market Value 2033 US$ 639.2 million
CAGR 2023 to 2033 7%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 High-end Cellomics Demand Outlook Compared to 2023 to 2033 Forecast

According to Future Market Insights (FMI), the sales of high-end cellomics have expanded at a CAGR of 4.9% from 2018 to 2022.

The demand for effective screening methods and techniques has surged in the last decade due to the rising prevalence of several genetic disorders and neurological diseases. This had a positive impact on the high-end cellomics market. Furthermore, initiatives undertaken by governments to promote advanced biotechnology research increase the installation of high-end cellomics instruments for drug discovery applications.

Cities of India such as Bangalore, Pune, Hyderabad, and Tamil Nadu have well-established biotechnology research infrastructures recognized globally, which is predicted to soar the demand for high-end research instruments.

Apart from India, China, and the United States of America, the governments of Japan, Brazil, the United Kingdom, and Australia are supporting their domestic biotechnology and bioscience industry through similar initiatives, shaping the high-end cellomics market demand analysis.

What are the Key Opportunities for High-end Cellomics Market Players?

  • Expansion of applications: High-end cellomics market players have the opportunity to explore and expand the applications of their systems in various fields, such as drug discovery, personalized medicine, regenerative medicine, and disease research.
  • Technological Advancements: Continuous advancements in hardware, imaging technologies, data analysis software, and automation present opportunities for market players to develop and offer many advanced and efficient high-end cellomics systems.
  • Collaborations and Partnerships: Collaborating with pharmaceutical companies, research institutions, and contract research organizations (CROs) can create opportunities for market players to access a wider customer base and expand their market presence.
  • Emerging Markets: Market players can explore and tap into emerging markets, particularly in the region such as Asia Pacific and Latin America, where there is a growing demand for advanced technologies in life sciences research and drug discovery.
  • Customization and Tailored Solutions: Offering customizable solutions and tailored packages for specific research needs can attract customers and provide a competitive edge in the market.
  • Integration of Artificial Intelligence (AI): Incorporating AI algorithms and machine learning capabilities into high-end cellomics systems can enhance data analysis, improve accuracy, and provide many insightful results, opening up opportunities for market players to leverage these technologies.
  • Outsourcing Services: Providing high-quality high content screening (HCS) services to pharmaceutical companies, biotechnology firms, and academic institutions as a specialized service provider or CRO can be a significant opportunity for market players.
  • Market Education and Awareness: Educating potential customers about the benefits and potential applications of high-end cellomics systems through seminars, workshops, and publications can create opportunities for market players to expand their customer base and drive market growth.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Can a High Price of High-end Cellomics Instruments Limit their Widespread Adoption?

  • High-end cellomics instruments integrate automated microscopy, image processing, and visualization tools into a single system, but their advanced features contribute to their higher price range.
  • The total cost of ownership for high-end cellomics instruments includes not only the instrument cost but also expenses for installation, maintenance, and services.
  • Budgetary constraints among academic research institutes, contract research organizations (CROs), pharmaceutical, and biotechnology companies can hinder the adoption of high-end cellomics instruments.
  • In price-sensitive markets like India, there is a trend of shifting toward alternative cell imaging analysis equipment, such as cell imaging instruments and flow cytometry.
  • The high cost of high-end cellomics instruments, combined with the availability of alternative instruments, is anticipated to negatively impact market growth.

Country-wise Insights

How Likely is the United States of America to Remain a Key Market for High-end Cellomics?

In 2022, the United States of America’s high-end cellomics market accounted for over 28.5% value share in North America.

Demand in the United States of America is primarily driven by a strong regional economy, the presence of refined research and healthcare facilities, and improved attention to overall health and well-being.

The country's supportive regulatory environment and access to funding further contribute to its position as a leading market for high-end cellomics.

How is Germany’s High-end Cellomics Market Projected to Fare?

Germany accounted for a 6.5% value share in 2022. Germany’s high-end cellomics market is projected to fare positively in the coming years.

Growing capital and venture investments for cellular research, technological developments in high-end cellomics solutions, cost restraint in pharma research and development, and the presence of key players have resulted in the high growth of Germany’s market.

What are the Factors Supporting High-end Cellomics Sales in Australia?

Australia’s market is anticipated to exhibit a 5.5% CAGR during the forecast period. The rising prevalence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s is one of the key factors driving the market growth. Similarly, the growing geriatric population is supplementing market growth in Australia.

What Facilitates the Demand in India’s High-end Cellomics Market?

The market in India is expected to advance at 9.2% CAGR from 2023 to 2033. Research activities in the biotechnology and bioscience field are increasing notably due to government support and the availability of funds, thus increasing the demand for high-end cellomics in India.

The Government of India is offering 100% foreign direct investment for biotechnology companies that are based outside India, and the GOI is offering public-private partnerships for companies based in India.

The Department of Biotechnology has supported the biotechnology research infrastructure including high-end high content screening systems, flow cytometry, imaging microarray, and high-resolution mass spectrometry facilities in Delhi and Mumbai respectively.

What is the Scope for Sales of High-end Cellomics in China?

The market in China is projected to exhibit a 7.7% CAGR during the forecast period and is expected to contribute significantly to the market in East Asia region. Government initiatives to spur the biotechnology industry in the region are creating growth opportunities in China.

China has included the biotechnology industry as one of the strategic priorities for development in terms of technology. Moreover, there were about 95 biotech-related deals till June 2020, drawing about US$ 12 billion deals.

In 2020, Everest Medicines Ltd and Maxwell Biosciences Co. Ltd. raised US$ 310 million in June and US$ 279 million respectively. These companies have strong oncology and immunology products in their pipelines, which require advanced instrumentation such as high-end HCS systems in the drug discovery phase for screening and compound profiling.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

What are the Sales Prospects in Drug Discovery?

High-end cellomics demand in drug discovery consistently rises, registering a high share of 55.42% in 2022. Increasing support for research and development activities, particularly for rare diseases, and the growing use of informatics in drug discovery led to demand for Drug Discovery.

Why is Demand for High-end Cellomics High in Pharmaceutical & Biotechnology Companies?

Pharmaceutical & biotechnology companies are currently leading the market. This sub-segment accounted for 52.03% value share in 2022.

Pharmaceutical & biotechnology companies are using this informatics software widely for pre-clinical research & development, compound screening and lead documentation, target identification, and rationalization of their drug discovery process. It becomes the key factor for propelling the growth of the Pharmaceutical & Biotechnology Companies segment.

How is the Competitive Landscape Structured within the High-end Cellomics Industry?

The competitive landscape within the high-end cellomics market is structured with multiple key players vying for market share and differentiation. The market consists of several prominent companies that offer high-end cellomics solutions and compete for customers. These players may vary in terms of size, market presence, and product offerings.

Market players are actively focusing on developing high-end cellomics instruments to capitalize on the growing market opportunity. These systems have increased software data analysis and data management capabilities. Quick image acquisition and multiplexing flexibility with high-performing lasers and an improved incubation environment are some of the benefits offered by these systems.

A Few of the Strategies Employed by the Market Players Include

  • Product innovation and development
  • Strategic partnerships and collaborations
  • Market expansion and geographic reach
  • Targeted marketing and branding efforts
  • Customer-centric approach and personalized solutions
  • Continuous improvement of customer support and services
  • Competitive pricing strategies
  • Focus on regulatory compliance and quality standards
  • Acquisitions and mergers to strengthen market position
  • Investment in research and development capabilities

Key Players Working in the Market:

  • PerkinElmer, Inc.
  • ThermoFisher Scientific, Inc.
  • Molecular Devices LLC (part of Danaher Corporation)
  • Yokogawa Electric Corporation

Key Developments in the Market:

  • ImageXpress Confocal HT.ai High Content HT.ai. (Molecular Devices LLC), ImageXpress Micro Confocal High-Content Imaging System (with water imaging technology) (Molecular Devices LLC), and Cell Voyager CV8000 (Yokogawa) are some of the recent launches by the industry players in the global market.
  • High-end cellomics are increasingly using machine learning methods for data interpretation and image analysis. These algorithms can swiftly identify and quantify cellular characteristics, increasing analysis speed and precision.
  • Organ-on-a-chip technology integrates microfluidics, tissue engineering, and cell culture to mimic the functioning of human organs in a lab setting. This method enables the study of cellular responses and interactions under more physiologically appropriate settings, assisting in drug discovery and toxicity assessment.
  • High-end cellomics is making a substantial contribution to cancer research by offering insights into tumor heterogeneity, metastasis, and medication resistance. Cellular analysis tools have enabled the identification of cancer biomarkers, the characterization of circulating tumor cells, and the evaluation of therapeutic efficacy.

Market by Category

By Application:

  • Academic Research/Basic Research
  • Drug Discovery
    • Primary & Secondary Screening
    • Target Identification & Validation
    • Invitro Toxicity Studies
    • Compound Profiling

By End-User:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Independent Contract Research Organizations (CROs)

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the High-end Cellomics Market?

The market is valued at US$ 325.1 million in 2023.

What is the Growth Potential of the Market?

The growth potential of the market is 7% through 2033.

Which Country Relishes Significant Market Share?

The United States market relishes 28.5% market share presently.

What is India’s Anticipated Growth Rate?

India is anticipated to expand at a CAGR of 9.2% through 2033.

How are Key Players Capitalizing on the Expanding Market?

Key players are focusing on creating high-end cellomics instruments to capitalize on the expanding market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        5.3.1. Academic Research/Basic Research

        5.3.2. Drug Discovery

            5.3.2.1. Primary & Secondary Screening

            5.3.2.2. Target Identification & Validation

            5.3.2.3. Invitro Toxicity Studies

            5.3.2.4. Compound Profiling

    5.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033

        6.3.1. Pharmaceutical & Biotechnology Companies

        6.3.2. Academic & Research Institutes

        6.3.3. Independent Contract Research Organizations (CROs)

    6.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Application

        8.2.3. By End-User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Application

        8.3.3. By End-User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Application

        9.2.3. By End-User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Application

        9.3.3. By End-User

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Application

        10.2.3. By End-User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Application

        10.3.3. By End-User

    10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Application

        11.2.3. By End-User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Application

        11.3.3. By End-User

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Application

        12.2.3. By End-User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Application

        12.3.3. By End-User

    12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Application

        13.2.3. By End-User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Application

        13.3.3. By End-User

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Application

        14.2.3. By End-User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Application

        14.3.3. By End-User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Application

            15.1.2.2. By End-User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Application

            15.2.2.2. By End-User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Application

            15.3.2.2. By End-User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Application

            15.4.2.2. By End-User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Application

            15.5.2.2. By End-User

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Application

            15.6.2.2. By End-User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Application

            15.7.2.2. By End-User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Application

            15.8.2.2. By End-User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Application

            15.9.2.2. By End-User

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Application

            15.10.2.2. By End-User

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Application

            15.11.2.2. By End-User

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Application

            15.12.2.2. By End-User

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Application

            15.13.2.2. By End-User

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Application

            15.14.2.2. By End-User

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Application

            15.15.2.2. By End-User

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Application

            15.16.2.2. By End-User

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Application

            15.17.2.2. By End-User

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Application

            15.18.2.2. By End-User

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Application

            15.19.2.2. By End-User

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Application

            15.20.2.2. By End-User

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Application

            15.21.2.2. By End-User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Application

        16.3.3. By End-User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Thermo Fisher Scientific Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. GE Healthcare

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. BD Biosciences

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Olympus Corporation

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. PerkinElmer Inc.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Merck KGaA

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Carl Zeiss AG

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Danaher Corporation

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Bio-Rad Laboratories, Inc.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Agilent Technologies, Inc.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Molecular Imaging Market

August 2023

REP-GB-724

306 pages

Healthcare

Specific Imaging Solution Market

April 2023

REP-GB-17079

322 pages

Explore Healthcare Insights

View Reports
Future Market Insights

High-end Cellomics Market

Schedule a Call